MeiraGTx Holdings plc filings document a clinical-stage genetic medicines company with ordinary shares listed on Nasdaq under MGTX. The company’s 8-K reports cover material definitive agreements, collaboration and license arrangements, asset purchases for genetic-medicine programs, Regulation FD clinical disclosures, operating and financial results, and amendments to note and warrant financing arrangements.
Its proxy materials describe shareholder voting matters, board governance, executive compensation, equity awards, and related corporate-governance disclosures. The filing record also documents capital structure, subsidiary guarantor arrangements, risk-oriented clinical and regulatory disclosures, and program-specific matters involving AAV-hAQP1, AAV-AIPL1, RPGR-related X-linked retinitis pigmentosa assets, and riboswitch technology.
MeiraGTx Holdings plc reports positive three-year follow-up data from its Phase 1 AQUAx study of AAV‑hAQP1, a one-time gene therapy for grade 2/3 late radiation‑induced xerostomia. The treatment was observed to be safe and well tolerated across doses, with no dose‑limiting toxicity or treatment‑related serious adverse events.
Clinically meaningful symptom improvements on the Xerostomia Questionnaire and increases in Unstimulated Whole Saliva Flow Rate were maintained out to 36 months, suggesting durable benefit. The company highlights RIX as a severe, lifelong condition with no effective treatments, affecting an estimated 165,000 patients in the U.S. and about 435,000 globally.
Market research cited by MeiraGTx shows strong physician enthusiasm, with approximately 78% clinician‑stated preference translating to around 52% projected usage after adjustment and roughly 90% estimated U.S. market access coverage. Based on commissioned research, the company estimates peak global annual revenue potential of about $3.7 billion, with a steady‑state of $3.2 billion globally and $2.0 billion peak and $1.8 billion steady‑state in the U.S. in the late 2030s, though these figures are forward‑looking and subject to significant development and regulatory risks outlined in its risk disclosures.
MeiraGTx Holdings plc chief development officer Stuart Naylor reported an open-market sale of 27,661 Ordinary Shares of MGTX on April 7, 2026. The shares were sold at a weighted average price of $9.36, in multiple trades between $9.11 and $9.52 per share.
After this transaction, Naylor directly holds 668,505 Ordinary Shares. The sale was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 9, 2025, indicating it was planned in advance rather than timed discretionarily.
MeiraGTx Holdings plc outlines its business as a vertically integrated, clinical-stage genetic medicines company focused on xerostomia, neurodegenerative disease and inherited retinal disorders. It highlights late-stage programs such as AAV‑hAQP1 for radiation‑induced xerostomia and AAV‑GAD for Parkinson’s disease, both supported by favorable early clinical data and U.S. FDA regenerative medicine designations.
The company emphasizes ownership of two GMP viral vector and plasmid manufacturing campuses in London and Shannon, designed to support clinical through commercial supply. MeiraGTx also describes a proprietary riboswitch gene regulation platform for orally controlled expression of biologics and cell therapies, and multiple strategic collaborations with Johnson & Johnson, Hologen and Eli Lilly that bring upfront payments, development funding and significant potential milestones.
MeiraGTx Holdings plc amended its credit facility with Perceptive, extending the notes’ maturity from August 2, 2026 to May 2, 2027 and committing to redeem $25.0 million of principal on or before June 30, 2026. Related warrants for 700,000 ordinary shares were repriced to $8.00 per share. The company reported 2025 revenue of $81.4 million, driven by a $75.0 million upfront license payment from Eli Lilly, and a net loss of $114.2 million versus $147.8 million in 2024. Cash and cash equivalents were $65.9 million as of December 31, 2025. Management believes existing cash, receivables and collaboration funding can support operations into the second half of 2027 and cover scheduled debt repayments of $25.0 million due June 2026 and $50.0 million due May 2027. The FDA granted Breakthrough Therapy Designation to AAV2-hAQP1 for Grade 2/3 radiation-induced xerostomia, and the company highlighted strategic collaborations with Eli Lilly and Hologen and progress in its riboswitch gene regulation platform.
MeiraGTx Holdings plc’s President and CEO Alexandria Forbes reported an open-market sale of 62,000 Ordinary Shares of MGTX. The shares were sold at a weighted average price of $7.41 per share in multiple transactions between $7.27 and $7.56.
The transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2025. Following these sales, Forbes directly holds 1,449,695 Ordinary Shares of MeiraGTx.
MeiraGTx Holdings plc chief medical officer Robert K. Zeldin reported equity award activity involving restricted share units and ordinary shares. On February 21, 2026, one quarter of a restricted share unit grant from February 21, 2023 vested, converting 7,500 restricted share units into 7,500 ordinary shares at no cash exercise price. In connection with this vesting, 2,952 ordinary shares were automatically withheld at a price of $7.45 per share to cover tax obligations, a tax-withholding disposition rather than an open-market sale. After these transactions, Zeldin directly held 172,888 ordinary shares.
MeiraGTx Holdings plc reported that its General Counsel and Secretary, Robert J. Wollin, acquired ordinary shares through the vesting of restricted share units. On February 21, 2026, one-quarter of a prior grant of 11,250 restricted share units vested and converted into 11,250 ordinary shares at no exercise price.
Following the conversion, 5,949 ordinary shares were withheld to cover tax obligations associated with the vesting, at a price of $7.45 per share. After these transactions, Wollin held 57,377 ordinary shares directly. These movements reflect routine equity compensation vesting and related tax withholding rather than open‑market trading.
MeiraGTx Holdings plc Chief Development Officer Stuart Naylor reported equity award activity related to previously granted restricted share units. On February 21, 2026, one-quarter of his restricted share units granted on February 21, 2023 vested, resulting in 25,000 restricted share units converting into 25,000 ordinary shares, with no exercise price. Following this vesting and conversion, his direct holdings briefly totaled 707,916 ordinary shares. To cover tax obligations on the vesting, 11,750 ordinary shares were withheld and disposed of at $7.45 per share, a tax-withholding disposition rather than an open-market sale, leaving him with 696,166 ordinary shares held directly.